Page last updated: 2024-12-07
ym 9429
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
YM 9429: a potent and specific teratogen; induces cleft palate in CD rats; inhibits dehydrocholesterol reductase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 115195 |
| SCHEMBL ID | 11443208 |
| SCHEMBL ID | 11443207 |
| MeSH ID | M0224744 |
Synonyms (15)
| Synonym |
|---|
| cis-1-(4-(p-monthane-8-yloxy)phenyl)piperidine |
| piperidine, 1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)-, cis- |
| 1-(4-(1-methyl-1-(cis-4-methylcyclohexyl)ethoxy)phenyl)piperidine |
| ym-9429 |
| cis-1-(4-(1-methyl-1-(4-methylcyclohexyl)ethoxy)phenyl)piperidine |
| ym9429 |
| cis-1-(4-(p-menthane-8-yloxy)phenyl)piperidine |
| ym 9429 |
| 72056-79-2 |
| 1-[4-[2-(4-methylcyclohexyl)propan-2-yloxy]phenyl]piperidine |
| SCHEMBL11443208 |
| SCHEMBL11443207 |
| 1-(4-{[2-(4-methylcyclohexyl)propan-2-yl]oxy}phenyl)piperidine |
| DTXSID10992785 |
| AKOS040754530 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||